Ergomed’s interim results highlight continued progression and impressive growth (net service revenue +53%, 36% organic) propelled by Drug Safety Monitoring and Medical Information, which nearly doubled YoY. New service contracts worth £23m were signed through to 31 July with an impressive backlog of contracted work of over £70m, providing the group with a high degree of revenue visibility. Following patient recruitment into the group’s Phase IIb trial evaluating PeproStat™ completing around six ....
18 Sep 2017
N+1 Singer - Ergomed - Strong H1 growth; PeproStat™ Phase IIb data expected in October
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Ergomed - Strong H1 growth; PeproStat™ Phase IIb data expected in October
- Published:
18 Sep 2017 -
Author:
Sheena Berry -
Pages:
3
Ergomed’s interim results highlight continued progression and impressive growth (net service revenue +53%, 36% organic) propelled by Drug Safety Monitoring and Medical Information, which nearly doubled YoY. New service contracts worth £23m were signed through to 31 July with an impressive backlog of contracted work of over £70m, providing the group with a high degree of revenue visibility. Following patient recruitment into the group’s Phase IIb trial evaluating PeproStat™ completing around six ....